Sarepta Therapeutics, Inc SRPT Stock Price, Quote & News

Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals. Analysts like Sarepta Therapeutics more than other Medical companies. sez photos The consensus rating score for Sarepta Therapeutics is 2.93 while the average consensus rating score for medical companies is 2.65. The company has carved out a niche in the competitive e-commerce sector.

Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Over the past year, e-commerce giant Shopify has made several important moves. After having held its prices steady for more than a decade, it increased them at the beginning of 2023.

• Move your mouse over a quarter or year to see how estimates have changed over time.
• The tech giant also decided to exit its logistics business — a move that will boost its bottom line over the long run.
• Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat’s FREE daily newsletter.
• The total cost received by the writing party (or parties) was $25.1K, with a price of $2290.0 per contract.

At that point, management will either have to be patient or end up reducing the cost of this gene therapy. The global Duchenne Muscular Dystrophy drug market size is expected to reach $4.11 billion by 2023. Thus, one way to expand its label of ELEVIDYS would be to receive approval for all ambulatory DMD patients regardless of age. In order to accomplish this task, everything is resting on the ongoing pivotal EMBARK study. This late-stage study is expected to evaluate the use of ELEVIDYS for the treatment of 120 ambulatory boys with DMD who are between the ages of 4 to 7 years of age.

Stock Money Flow

According to TipRanks.com, Tsao is a 4-star analyst with an average return of 6.7% and a 37.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Protagonist Therapeutics. According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.2% and a 45.7% success rate.

Again, the goal of this study is to target non-ambulatory DMD patients. However, this study targeting this specific DMD patient population is going to have a different endpoint. The primary endpoint for this study is going to be a change from baseline in total score of performance of upper limb version 2, which is going to be evaluated over a 72-week period.

Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapy

Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
similar fashion.

Sarepta should maintain its revenue momentum in the mid-term thanks to Elevidys. It will also allow the company to move closer to profitability. The company’s net loss in the second quarter was $0.27 per share, better than the net loss of $2.65 per share it reported in the year-ago period. The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics’ first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD), an inherited progressive muscle wasting … SRPT, +0.60% said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the rare genetic disorder Duchenne muscular dystrophy, or DMD. WASHINGTON — The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment’s abilit…

SRPT Stock – Frequently Asked Questions

Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning out. SRPT, -0.90% said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $102 million and will use the proceeds for R&D. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

Most of Sarepta’s product candidates are at an early stage of development. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha’s Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service.

Analyst Recommendations

Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant’s community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. Enter your email address below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter.

There were open contracts at this strike prior to today, and today 2012 contract(s) were bought and sold. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.

Key Data

Lastly, Shopify should benefit from the trends in the e-commerce industry, which is still in high-growth mode. With the stock trading at just under $64, investors with $500 to deploy now can get seven shares with change to spare. In addition, the https://1investing.in/ company has said it expects “that nearly all infusions of Elevidys will be subject to a statutory discount.” In other words, few will be paying the full list price. It will be able to accomplish this with the ongoing trial known as ENVISION.

• Regarding MRK MRK, we observe a call option trade with neutral sentiment. The total cost received by the writing party (or parties) was $28.7K, with a price of $1150.0 per contract. There were 1090 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. • For ABBV ABBV, we notice a call option sweep that happens to be bearish, expiring in 491 day(s) on January 17, 2025. This event was a transfer of 75 contract(s) at a $180.00 strike. This particular call needed to be split into 12 different trades to become filled.

Time to Upgrade!

According to analysts, Sarepta Therapeutics’s stock has a predicted upside of 36.80% based on their 12-month price targets. What’s even more important is that Sarepta is demonstrating its ability to develop novel therapies for difficult-to-treat diseases. And its pipeline features other candidates that target this disease. Sarepta Therapeutics may not yet be profitable, but the company looks like a rising star in the biotech industry, and that’s one of the things that makes the company attractive.

• For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.
• Food and Drug Administration has indicated after talks with the company that it’s working toward granting accelerated approval of SR…
• Investors won’t have to wait long to see results from this EMBARK study.
• This late-stage study is expected to evaluate the use of ELEVIDYS for the treatment of 120 ambulatory boys with DMD who are between the ages of 4 to 7 years of age.
• Again, the goal of this study is to target non-ambulatory DMD patients.

Sarepta’s most recent therapy approval in June was its most important yet. The treatment in question is called Elevidys, the first gene therapy approved by the Food and Drug Administration to target the underlying causes of DMD. Elevidys is only indicated to treat patients ages 4 to 5 for now. The Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and personal essay.